このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

ステージ II または III の非小細胞肺癌患者における放射線療法とその後のアテゾリズマブの研究

2026年11月17日 更新者:National Cancer Institute (NCI)

パフォーマンスステータスが境界線のステージ II または III の NSCLC 患者におけるアテゾリズマブによる地固め療法に続く少分割放射線療法のパイロット研究

This phase II trial studies the side effects of radiation therapy followed by atezolizumab in treating patients with stage II or III non-small cell lung cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more cancer cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to test the safety and effectiveness of radiation therapy followed by atezolizumab and find out what side effects, if any, it has on patient's non-small cell lung cancer.

調査の概要

状態

積極的、募集していない

条件

介入・治療

詳細な説明

PRIMARY OBJECTIVE:

I. To evaluate the rate of grade 3-5 treatment-related adverse events (TRAEs) in patients who are not candidates for surgery or concurrent chemoradiation and who have either performance status 0-2 and stage II or performance status 2 and stage III non-small cell lung cancer (NSCLC), treated with hypofractionated thoracic radiotherapy followed by atezolizumab.

SECONDARY OBJECTIVES:

I. To evaluate response rate (confirmed and unconfirmed, complete and partial by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) from Registration Step 2 in the subset of patients with measurable disease.

II. To evaluate response rate (confirmed and unconfirmed, complete and partial by RECIST 1.1) during radiation therapy in the subset of patients with measurable disease.

III. To evaluate progression free survival (PFS) from Registration Step 2 by RECIST 1.1.

IV. To evaluate overall survival (OS) from Registration Step 2. V. To evaluate the frequency and severity of toxicities.

ADDITIONAL OBJECTIVE:

I. To bank blood and archival tissue for future research.

OUTLINE:

RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week over 3 weeks for 15 fractions in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) scan and may undergo magnetic resonance imaging (MRI) throughout the study, as well as blood sample collection on study.

After completion of study treatment, patients are followed up at 6 weeks, every 12 months for the 1 year, then every 6 months until 3 years after study start.

研究の種類

介入

入学 (推定)

47

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35233
        • University of Alabama at Birmingham Cancer Center
    • Alaska
      • Anchorage、Alaska、アメリカ、98508
        • Anchorage Associates in Radiation Medicine
      • Anchorage、Alaska、アメリカ、99508
        • Alaska Breast Care and Surgery LLC
      • Anchorage、Alaska、アメリカ、99508
        • Alaska Oncology and Hematology LLC
      • Anchorage、Alaska、アメリカ、99508
        • Alaska Women's Cancer Care
      • Anchorage、Alaska、アメリカ、99508
        • Katmai Oncology Group
      • Anchorage、Alaska、アメリカ、99508
        • Providence Alaska Medical Center
    • Arkansas
      • Jonesboro、Arkansas、アメリカ、72401
        • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
    • California
      • Sacramento、California、アメリカ、95817
        • University of California Davis Comprehensive Cancer Center
    • Colorado
      • Denver、Colorado、アメリカ、80210
        • AdventHealth Porter
      • Littleton、Colorado、アメリカ、80122
        • AdventHealth Littleton
      • Parker、Colorado、アメリカ、80138
        • AdventHealth Parker
    • Florida
      • Aventura、Florida、アメリカ、33180
        • Mount Sinai Comprehensive Cancer Center at Aventura
      • Miami Beach、Florida、アメリカ、33140
        • Mount Sinai Medical Center
    • Georgia
      • Augusta、Georgia、アメリカ、30912
        • Augusta University Medical Center
      • Newnan、Georgia、アメリカ、30265
        • CTCA at Southeastern Regional Medical Center
    • Hawaii
      • Honolulu、Hawaii、アメリカ、96813
        • Queen's Medical Center
      • Honolulu、Hawaii、アメリカ、96817
        • The Cancer Center of Hawaii-Liliha
      • Honolulu、Hawaii、アメリカ、96813
        • Hawaii Cancer Care Inc - Waterfront Plaza
      • Honolulu、Hawaii、アメリカ、96813
        • Queen's Cancer Cenrer - POB I
      • Honolulu、Hawaii、アメリカ、96813
        • Straub Clinic and Hospital
      • Honolulu、Hawaii、アメリカ、96813
        • University of Hawaii Cancer Center
      • Honolulu、Hawaii、アメリカ、96817
        • Hawaii Cancer Care Inc-Liliha
      • Honolulu、Hawaii、アメリカ、96817
        • Queen's Cancer Center - Kuakini
      • Honolulu、Hawaii、アメリカ、96826
        • Kapiolani Medical Center for Women and Children
      • Honolulu、Hawaii、アメリカ、96813
        • Island Urology
      • Lihue、Hawaii、アメリカ、96766
        • Wilcox Memorial Hospital and Kauai Medical Clinic
      • ‘Aiea、Hawaii、アメリカ、96701
        • Hawaii Cancer Care - Westridge
      • ‘Aiea、Hawaii、アメリカ、96701
        • Pali Momi Medical Center
      • ‘Aiea、Hawaii、アメリカ、96701
        • Queen's Cancer Center - Pearlridge
      • ‘Aiea、Hawaii、アメリカ、96701
        • The Cancer Center of Hawaii-Pali Momi
    • Idaho
      • Nampa、Idaho、アメリカ、83687
        • Saint Alphonsus Cancer Care Center-Nampa
    • Illinois
      • Bloomington、Illinois、アメリカ、61704
        • Illinois CancerCare-Bloomington
      • Canton、Illinois、アメリカ、61520
        • Illinois CancerCare-Canton
      • Carthage、Illinois、アメリカ、62321
        • Illinois CancerCare-Carthage
      • Centralia、Illinois、アメリカ、62801
        • Centralia Oncology Clinic
      • Centralia、Illinois、アメリカ、62801
        • Saint Mary's Hospital
      • Chicago、Illinois、アメリカ、60612
        • University of Illinois
      • Chicago、Illinois、アメリカ、60612
        • Jesse Brown Veterans Affairs Medical Center
      • Danville、Illinois、アメリカ、61832
        • Carle at The Riverfront
      • Decatur、Illinois、アメリカ、62526
        • Decatur Memorial Hospital
      • Decatur、Illinois、アメリカ、62526
        • Cancer Care Specialists of Illinois - Decatur
      • Effingham、Illinois、アメリカ、62401
        • Crossroads Cancer Center
      • Effingham、Illinois、アメリカ、62401
        • Carle Physician Group-Effingham
      • Eureka、Illinois、アメリカ、61530
        • Illinois CancerCare-Eureka
      • Galesburg、Illinois、アメリカ、61401
        • Illinois CancerCare-Galesburg
      • Kewanee、Illinois、アメリカ、61443
        • Illinois CancerCare-Kewanee Clinic
      • Macomb、Illinois、アメリカ、61455
        • Illinois CancerCare-Macomb
      • Mattoon、Illinois、アメリカ、61938
        • Carle Physician Group-Mattoon/Charleston
      • O'Fallon、Illinois、アメリカ、62269
        • Cancer Care Center of O'Fallon
      • O'Fallon、Illinois、アメリカ、62269
        • HSHS Saint Elizabeth's Hospital
      • Ottawa、Illinois、アメリカ、61350
        • Illinois CancerCare-Ottawa Clinic
      • Pekin、Illinois、アメリカ、61554
        • Illinois CancerCare-Pekin
      • Peoria、Illinois、アメリカ、61636
        • Methodist Medical Center of Illinois
      • Peoria、Illinois、アメリカ、61615
        • Illinois CancerCare-Peoria
      • Peru、Illinois、アメリカ、61354
        • Illinois CancerCare-Peru
      • Princeton、Illinois、アメリカ、61356
        • Illinois CancerCare-Princeton
      • Springfield、Illinois、アメリカ、62702
        • Southern Illinois University School of Medicine
      • Springfield、Illinois、アメリカ、62702
        • Springfield Clinic
      • Springfield、Illinois、アメリカ、62781
        • Springfield Memorial Hospital
      • Urbana、Illinois、アメリカ、61801
        • Carle Cancer Center
      • Urbana、Illinois、アメリカ、61801
        • The Carle Foundation Hospital
      • Washington、Illinois、アメリカ、61571
        • Illinois CancerCare - Washington
    • Iowa
      • Ames、Iowa、アメリカ、50010
        • Mary Greeley Medical Center
      • Ames、Iowa、アメリカ、50010
        • McFarland Clinic - Ames
      • Ankeny、Iowa、アメリカ、50023
        • UI Health Care Mission Cancer and Blood - Ankeny Clinic
      • Clive、Iowa、アメリカ、50325
        • Mercy Cancer Center-West Lakes
      • Clive、Iowa、アメリカ、50325
        • UI Health Care Mission Cancer and Blood - West Des Moines Clinic
      • Creston、Iowa、アメリカ、50801
        • Greater Regional Medical Center
      • Des Moines、Iowa、アメリカ、50309
        • Iowa Methodist Medical Center
      • Des Moines、Iowa、アメリカ、50314
        • Mercy Medical Center - Des Moines
      • Des Moines、Iowa、アメリカ、50314
        • Broadlawns Medical Center
      • Des Moines、Iowa、アメリカ、50316
        • Iowa Lutheran Hospital
      • Des Moines、Iowa、アメリカ、50309
        • UI Health Care Mission Cancer and Blood - Des Moines Clinic
      • Des Moines、Iowa、アメリカ、50314
        • UI Health Care Mission Cancer and Blood - Laurel Clinic
      • Waukee、Iowa、アメリカ、50263
        • UI Health Care Mission Cancer and Blood - Waukee Clinic
      • West Des Moines、Iowa、アメリカ、50266-7700
        • Methodist West Hospital
      • West Des Moines、Iowa、アメリカ、50266
        • Mercy Medical Center-West Lakes
    • Kentucky
      • Lexington、Kentucky、アメリカ、40504
        • Saint Joseph Radiation Oncology Resource Center
      • Lexington、Kentucky、アメリカ、40509
        • CommonSpirit Saint Joseph Medical Center - East Lexington
      • Lexington、Kentucky、アメリカ、40504
        • CommonSpirit Saint Joseph Hospital - Lexington
    • Massachusetts
      • Beverly、Massachusetts、アメリカ、01915
        • Beverly Hospital
      • Burlington、Massachusetts、アメリカ、01805
        • Lahey Clinic
      • Gloucester、Massachusetts、アメリカ、01930
        • Addison Gilbert Hospital
      • Peabody、Massachusetts、アメリカ、01960
        • Lahey Clinic Peabody
      • Winchester、Massachusetts、アメリカ、01890
        • Beth Israel Deaconess Medical Center/Winchester Center for Cancer Care
    • Michigan
      • Novi、Michigan、アメリカ、48374
        • Henry Ford Health Providence Novi Hospital
      • Southfield、Michigan、アメリカ、48075
        • Henry Ford Health Providence Southfield Hospital
    • Minnesota
      • Edina、Minnesota、アメリカ、55435
        • Fairview Southdale Hospital
      • Minneapolis、Minnesota、アメリカ、55415
        • Hennepin County Medical Center
      • Minneapolis、Minnesota、アメリカ、55454
        • Health Partners Inc
      • Saint Paul、Minnesota、アメリカ、55101
        • Regions Hospital
      • Stillwater、Minnesota、アメリカ、55082
        • Lakeview Hospital
    • Mississippi
      • Southhaven、Mississippi、アメリカ、38671
        • Baptist Memorial Hospital and Cancer Center-Desoto
    • Missouri
      • Cape Girardeau、Missouri、アメリカ、63703
        • Saint Francis Medical Center
      • Farmington、Missouri、アメリカ、63640
        • Parkland Health Center - Farmington
      • Rolla、Missouri、アメリカ、65401
        • Mercy Clinic-Rolla-Cancer and Hematology
      • Rolla、Missouri、アメリカ、65401
        • Phelps Health Delbert Day Cancer Institute
      • Sainte Genevieve、Missouri、アメリカ、63670
        • Sainte Genevieve County Memorial Hospital
      • Springfield、Missouri、アメリカ、65804
        • Mercy Hospital Springfield
      • St Louis、Missouri、アメリカ、63131
        • Missouri Baptist Medical Center
      • Sullivan、Missouri、アメリカ、63080
        • Missouri Baptist Sullivan Hospital
    • Montana
      • Bozeman、Montana、アメリカ、59715
        • Bozeman Health Deaconess Hospital
      • Great Falls、Montana、アメリカ、59405
        • Benefis Sletten Cancer Institute
      • Kalispell、Montana、アメリカ、59901
        • Logan Health Medical Center
    • New Mexico
      • Albuquerque、New Mexico、アメリカ、87106
        • University of New Mexico Cancer Center
    • New York
      • The Bronx、New York、アメリカ、10461
        • Montefiore Medical Center-Einstein Campus
      • The Bronx、New York、アメリカ、10467
        • Montefiore Medical Center - Moses Campus
      • The Bronx、New York、アメリカ、10461
        • Montefiore Medical Center-Weiler Hospital
    • Ohio
      • Centerville、Ohio、アメリカ、45459
        • Miami Valley Hospital South
      • Centerville、Ohio、アメリカ、45459
        • Dayton Physicians LLC-Miami Valley South
      • Dayton、Ohio、アメリカ、45409
        • Miami Valley Hospital
      • Dayton、Ohio、アメリカ、45415
        • Miami Valley Hospital North
      • Dayton、Ohio、アメリカ、45415
        • Dayton Physician LLC - Englewood
      • Dayton、Ohio、アメリカ、45409
        • Premier Blood and Cancer Center
      • Franklin、Ohio、アメリカ、45005-1066
        • Atrium Medical Center-Middletown Regional Hospital
      • Greenville、Ohio、アメリカ、45331
        • Miami Valley Cancer Care and Infusion
      • Troy、Ohio、アメリカ、45373
        • Upper Valley Medical Center
      • Troy、Ohio、アメリカ、45373
        • Dayton Physicians LLC - Troy
    • Oklahoma
      • Lawton、Oklahoma、アメリカ、73505
        • Cancer Centers of Southwest Oklahoma Research
      • Oklahoma City、Oklahoma、アメリカ、73104
        • University of Oklahoma Health Sciences Center
    • Oregon
      • Clackamas、Oregon、アメリカ、97015
        • Clackamas Radiation Oncology Center
      • Portland、Oregon、アメリカ、97239
        • Oregon Health and Science University
      • Portland、Oregon、アメリカ、97213
        • Providence Portland Medical Center
      • Portland、Oregon、アメリカ、97225
        • Providence Saint Vincent Medical Center
    • Pennsylvania
      • Erie、Pennsylvania、アメリカ、16505
        • UPMC Hillman Cancer Center Erie
      • Farrell、Pennsylvania、アメリカ、16121
        • UPMC Cancer Center at UPMC Horizon
      • Greensburg、Pennsylvania、アメリカ、15601
        • UPMC Cancer Centers - Arnold Palmer Pavilion
      • Greenville、Pennsylvania、アメリカ、16125
        • UPMC Hillman Cancer Center in Greenville/UPMC Horizon
      • Monroeville、Pennsylvania、アメリカ、15146
        • UPMC Hillman Cancer Center - Monroeville
      • Monroeville、Pennsylvania、アメリカ、15146
        • UPMC Cancer Center - Monroeville
      • New Castle、Pennsylvania、アメリカ、16105
        • UPMC Hillman Cancer Center - New Castle
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC Hillman Cancer Center
      • Pittsburgh、Pennsylvania、アメリカ、15232
        • UPMC-Shadyside Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15215
        • UPMC-Saint Margaret
      • Pittsburgh、Pennsylvania、アメリカ、15237
        • UPMC-Passavant Hospital
      • Pittsburgh、Pennsylvania、アメリカ、15243
        • UPMC-Saint Clair Hospital Cancer Center
      • Seneca、Pennsylvania、アメリカ、16346
        • UPMC Cancer Center at UPMC Northwest
      • Washington、Pennsylvania、アメリカ、15301
        • UPMC Washington Hospital Radiation Oncology
      • Washington、Pennsylvania、アメリカ、15301
        • UPMC Cancer Center-Washington
    • Tennessee
      • Collierville、Tennessee、アメリカ、38017
        • Baptist Memorial Hospital and Cancer Center-Collierville
      • Memphis、Tennessee、アメリカ、38120
        • Baptist Memorial Hospital and Cancer Center-Memphis
    • Texas
      • Dallas、Texas、アメリカ、75235
        • Parkland Memorial Hospital
      • Dallas、Texas、アメリカ、75390
        • UT Southwestern/Simmons Cancer Center-Dallas
      • Dallas、Texas、アメリカ、75237
        • UT Southwestern Simmons Cancer Center - RedBird
      • Fort Worth、Texas、アメリカ、76104
        • UT Southwestern/Simmons Cancer Center-Fort Worth
      • Richardson、Texas、アメリカ、75080
        • UT Southwestern Clinical Center at Richardson/Plano
      • San Antonio、Texas、アメリカ、78229
        • University of Texas Health Science Center at San Antonio
    • Washington
      • Seattle、Washington、アメリカ、98107
        • Swedish Medical Center-Ballard Campus
      • Seattle、Washington、アメリカ、98122
        • Swedish Medical Center-First Hill
      • Seattle、Washington、アメリカ、98122-5711
        • Swedish Medical Center-Cherry Hill
    • Wisconsin
      • Appleton、Wisconsin、アメリカ、54915
        • Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
      • Brookfield、Wisconsin、アメリカ、53045
        • Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
      • Chilton、Wisconsin、アメリカ、53014
        • Ascension Calumet Hospital-Chilton
      • Eau Claire、Wisconsin、アメリカ、54701
        • Marshfield Medical Center-EC Cancer Center
      • Franklin、Wisconsin、アメリカ、53132
        • Ascension Southeast Wisconsin Hospital - Franklin
      • Franklin、Wisconsin、アメリカ、53132
        • Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
      • Marshfield、Wisconsin、アメリカ、54449
        • Marshfield Medical Center-Marshfield
      • Mequon、Wisconsin、アメリカ、53097
        • Ascension Columbia Saint Mary's Hospital-Ozaukee Campus-Mequon
      • Milwaukee、Wisconsin、アメリカ、53210
        • Ascension Southeast Wisconsin Hospital-Saint Joseph-Milwaukee
      • Milwaukee、Wisconsin、アメリカ、53211
        • Ascension Columbia Saint Mary's Hospital-Milwaukee Campus
      • Milwaukee、Wisconsin、アメリカ、53215
        • Ascension Saint Francis Hospital-Milwaukee
      • Minocqua、Wisconsin、アメリカ、54548
        • Marshfield Medical Center - Minocqua
      • New Richmond、Wisconsin、アメリカ、54017
        • Cancer Center of Western Wisconsin
      • Oshkosh、Wisconsin、アメリカ、54904
        • Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
      • Racine、Wisconsin、アメリカ、53405
        • Ascension All Saints Hospital-Spring Street-Racine
      • Rice Lake、Wisconsin、アメリカ、54868
        • Marshfield Medical Center-Rice Lake
      • Stevens Point、Wisconsin、アメリカ、54482
        • Marshfield Medical Center-River Region at Stevens Point
      • Wauwatosa、Wisconsin、アメリカ、53226
        • Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
      • Weston、Wisconsin、アメリカ、54476
        • Marshfield Medical Center - Weston

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • REGISTRATION STEP 1: Participants must have pathologic (cytological or histological) proof of non-small cell lung cancer (NSCLC)
  • REGISTRATION STEP 1: Participants must have stage III NSCLC with Zubrod performance status of 2 or stage II NSCLC with Zubrod performance status of 0-2
  • REGISTRATION STEP 1: Participants must not be candidates for surgical resection in the opinion of the treating investigator. Participants whose disease was previously resected must have experienced local or regional recurrence at least 12 months after resection
  • REGISTRATION STEP 1: Participants must not be candidates for concurrent chemoradiation in the opinion of the treating investigator
  • REGISTRATION STEP 1: Participants must have measurable or non-measurable disease documented by CT or MRI. Measurable disease must be assessed within 28 days prior to Registration Step 1. Non-measurable disease must be assessed within 42 days prior to Step 1 registration. The CT from a combined positron emission tomography (PET)/CT may be used only if it is of diagnostic quality. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1)
  • REGISTRATION STEP 1: Participants must have an MRI or CT scan of the brain with contrast within 28 days prior to Registration Step 1
  • REGISTRATION STEP 1: Participants' disease must fit within the radiation constraints in the opinion of a local radiation oncologist
  • REGISTRATION STEP 1: Participants may have received prior treatment for their lung cancer, including surgery, chemotherapy, targeted agents, and/or radiation treatment. At least 12 months must have elapsed since last treatment
  • REGISTRATION STEP 1: Participants may have had prior radiation therapy as long as the irradiated area does not overlap with the radiation field targeted for this study
  • REGISTRATION STEP 1: Participants must have recovered from any adverse effects of prior major surgery to the satisfaction of the treating physician. Biopsies and central IV access placement are not considered major surgery
  • REGISTRATION STEP 1: Absolute neutrophil count (ANC) >= 1500/mcl (obtained within 28 days prior to Registration Step 1)
  • REGISTRATION STEP 1: Platelet count >= 100,000/mcl (obtained within 28 days prior to Registration Step 1)
  • REGISTRATION STEP 1: Hemoglobin >= 9 grams/dL (obtained within 28 days prior to Registration Step 1)
  • REGISTRATION STEP 1: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (obtained within 28 days prior to Registration Step 1)
  • REGISTRATION STEP 1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (obtained within 28 days prior to Registration Step 1)
  • REGISTRATION STEP 1: Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 40 mL/min (obtained within 28 days prior to Registration Step 1)
  • REGISTRATION STEP 1: Participants must have percent predicted diffusing capacity of the lungs for carbon monoxide (DLCO) of at least 40% documented within 90 days prior to Registration Step 1
  • REGISTRATION STEP 1: Patient must not have had a prior history of interstitial lung disease or > grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version 5) pneumonitis
  • REGISTRATION STEP 1: Participants must not have active autoimmune disease requiring therapy within the past 6 months
  • REGISTRATION STEP 1: Participants must not have an active infection requiring therapy
  • REGISTRATION STEP 1: Participants must be ≥ 18 years old
  • REGISTRATION STEP 1: Participants must not be pregnant or nursing because atezolizumab has not been studied in pregnant or nursing women and the mechanism of action is expected to cause fetal harm. Women/men of reproductive potential must have agreed to use an effective contraceptive method while on protocol treatment and for five months after last dose of atezolizumab. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures
  • REGISTRATION STEP 1: Participants with known human immunodeficiency virus (HIV) infection must be on effective anti-retroviral therapy and must have undetectable viral load at their most recent viral load test and within 6 months prior to Registration Step 1
  • REGISTRATION STEP 1: Patient must be tested for hepatitis B within 28 days prior to Registration Step 1. Patient must not have active (chronic or acute) hepatitis B virus (HBV) infection. Patients may have past or resolved HBV infection. Active HBV is defined as having a positive hepatitis B surface antigen (HBsAg) test. Past or resolved HBV is defined as having a negative HBsAG test and a positive total hepatitis B core antibody (HBcAb) test
  • REGISTRATION STEP 1: Patients must not have active hepatitis C virus (HCV) infection. Active HCV is defined as having a positive HCV antibody test followed by a positive HCV ribonucleic acid (RNA) test. Patient must have an HCV antibody test within 28 days prior to Registration Step 1. If the HCV antibody test is positive, the patient must also have an HCV quantitative RNA test within 28 days prior to Registration Step 1
  • REGISTRATION STEP 1: No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for three years. Participants with localized prostate cancer who are being followed by an active surveillance program are also eligible
  • REGISTRATION STEP 1: Participants must be offered optional participation in banking of specimens for future research
  • REGISTRATION STEP 1: Participants must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines
  • REGISTRATION STEP 1: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
  • REGISTRATION STEP 2: Participants must be registered to Step 2 within 42 days after completion of radiation treatment. Participants must have received at least 44 Gy of radiation treatment
  • REGISTRATION STEP 2: Participants must have no evidence of progression per RECIST 1.1 on CT scan of the chest, abdomen, and pelvis performed between 2 and 5 weeks after completion of radiation therapy
  • REGISTRATION STEP 2: Any toxicities from radiation therapy must have resolved to < grade 2
  • REGISTRATION STEP 2: ANC >= 1.5 x 10^3/uL (obtained within 28 days prior to Registration Step 2)
  • REGISTRATION STEP 2: Platelet count >= 100 x 10^3/uL (obtained within 28 days prior to Registration Step 2)
  • REGISTRATION STEP 2: Hemoglobin >= 9 grams/dL (obtained within 28 days prior to Registration Step 2)
  • REGISTRATION STEP 2: Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (obtained within 28 days prior to Registration Step 2)
  • REGISTRATION STEP 2: AST and ALT =< 2.5 x IULN (obtained within 28 days prior to Registration Step 2)
  • REGISTRATION STEP 2: Serum creatinine =< 1.5 x IULN OR measured or calculated creatinine clearance >= 40 mL/min (obtained within 28 days prior to Registration Step 2)
  • REGISTRATION STEP 2: Participants must not have received steroids in doses of more than prednisone 10 mg daily or equivalent within 14 days prior to Registration Step 2
  • REGISTRATION STEP 2: Participants must not have received a live vaccine within 28 days prior to Registration Step 2

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (hypofractionated radiation therapy, atezolizumab)

RADIATION THERAPY: Patients undergo hypofractionated radiation therapy 5 days per week over 3 weeks for 15 fractions in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION: Patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Cycles repeat every 21 days for up to 12 months (maximum of 17 cycles) in the absence of disease progression or unacceptable toxicity. Patients undergo CT scan and may undergo MRI throughout the study, as well as blood sample collection on study.

Undergo blood sample collection

他の名前:
  • 生物学的サンプルの収集
  • 採取された生体試料
  • 標本収集
  • サンプル収集

Undergo MRI

他の名前:
  • MRI
  • 磁気共鳴
  • 磁気共鳴画像スキャン
  • 医用画像、磁気共鳴 / 核磁気共鳴
  • 氏
  • MRイメージング
  • MRI スキャン
  • NMRイメージング
  • NMRI
  • 核磁気共鳴イメージング
  • 磁気共鳴画像法 (MRI)
  • sMRI
  • 磁気共鳴画像法(手順)
  • 構造MRI

Undergo CT scan

他の名前:
  • CT
  • 猫
  • CATスキャン
  • コンピューター断層撮影
  • コンピュータ化されたアキシャルトモグラフィー
  • CTスキャン
  • トモグラフィー
  • コンピューター断層撮影 (手順)
  • コンピューター断層撮影 (CT) スキャン
  • 診断CATスキャン
  • 診断CATスキャンサービスタイプ

Given IV

他の名前:
  • テセントリク
  • MPDL3280A
  • RO5541267
  • RG7446
  • MPDL 328OA
  • MPDL-3280A
  • MPDL328OA
  • RG-7446
  • RO 5541267
  • RO-5541267

Undergo hypofractionated radiation therapy

他の名前:
  • 少分割放射線療法
  • 低分画
  • 放射線、過分画

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Rate of grade 3-5 adverse events
時間枠:From baseline, until 180 days from Step 2 registration

Individual toxicities with possible, probable or likely attribution to treatment along with the overall rate of grade 3, 4 or 5 toxicities attributable to treatment will be summarized.

From baseline, until 180 days from Step 2 registration

二次結果の測定

結果測定
メジャーの説明
時間枠
Incidence of adverse events
時間枠:Up to 3 years

Individual toxicities with possible, probable or likely attribution to treatment along with the overall rate of grade 3, 4 or 5 toxicities attributable to treatment will be summarized.

Up to 3 years
Response rate (confirmed and unconfirmed, complete and partial by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) in the subset of patients with measurable disease (Registration Step 2)
時間枠:After atezolizumab treatment

Binary endpoints will be summarized as proportions with 95% Clopper-Pearson confidence intervals.

After atezolizumab treatment
Response rate (confirmed and unconfirmed, complete and partial by RECIST 1.1) in the subset of patients with measurable disease (Registration Step 1)
時間枠:During radiation therapy

Binary endpoints will be summarized as proportions with 95% Clopper-Pearson confidence intervals.

During radiation therapy
Progression-free survival
時間枠:From date of Step 2 registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years

Estimated using the method of Kaplan-Meier. 95% confidence for the medians will be constructed using the method of Brookmeyer-Crowley.

From date of Step 2 registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years
Overall survival
時間枠:From date of Step 2 registration to date of death due to any cause, assessed up to 3 years

Estimated using the method of Kaplan-Meier. 95% confidence for the medians will be constructed using the method of Brookmeyer-Crowley.

From date of Step 2 registration to date of death due to any cause, assessed up to 3 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Raid Aljumaily、SWOG Cancer Research Network

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年1月13日

一次修了 (推定)

2027年6月1日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2020年3月16日

QC基準を満たした最初の提出物

2020年3月16日

最初の投稿 (実際)

2020年3月17日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月18日

QC基準を満たした最後の更新が送信されました

2026年11月17日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • NCI-2020-01543
  • U10CA180888 (米国 NIH グラント/契約)
  • NCI-2020-01543 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
  • S1933 (その他の識別子:CTEP)
  • S1933 (その他の識別子:SWOG)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。